Healthpeak Raises 2026 FFO Guidance as Lab and Senior Housing Improve

What happened

Healthpeak Properties reported second‑quarter 2026 adjusted funds from operations of $0.46 per share and lifted its full‑year adjusted FFO guidance by $0.02 to $1.73–$1.77, citing better‑than‑expected same‑store NOI momentum in its lab and senior housing segments. The update marks an early sign that the lab leasing environment is stabilizing after several quarters of occupancy pressure and impairments noted in the master report. Senior housing continues to recover, now providing a stronger offset to any residual lab softness. With the dividend covered at a payout ratio in the low‑70s, the raised guidance supports the thesis that per‑share FFO can grow in the low‑single‑digits despite higher interest costs. The news adds conviction to the base‑case scenario of mid‑teens total returns from the current entry level.

Implication

The guidance raise, driven by lab and senior housing, directly addresses the bear case’s fear of prolonged lab weakness and suggests the lab trough may be shallower than the master report assumed. With outpatient cash NOI growing ~4% and CCRCs well above 2019 levels, total same‑store growth could re‑accelerate toward the mid‑single digits, enabling modest FFO/share gains. This increases the probability of the base case and edges the stock closer to the bull scenario if the lab recovery accelerates. However, the thesis remains sensitive to interest rates and lab oversupply, so investors should monitor upcoming leasing data and balance‑sheet metrics. At the current price, the raised guidance reinforces the attractive entry, making the risk/reward more compelling for a 12‑month hold.

Thesis delta

The Q2 2026 update shifts the thesis from cautious optimism to increased confidence. Lab same‑store NOI expectations are improving sooner than modeled, reducing the risk of a sustained drag on total portfolio growth. While the base‑case implied value of $18 remains achievable, the odds of the bull case ($20) rise if the lab recovery persists, though higher rates and leverage remain key constraints.